One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The RX mirror and exact official label differ for moderate-renal mCRPC dosing with enzalutamide. The disputed mirror extract is documentation, not permission.
What to reconcile: Read the newly dated official section and have oncology/pharmacy adjudicate the discrepancy. Do not average doses or confuse breast-cancer and mCRPC regimens.
Open this note and its source referencesThe current official label states 0.35 mg daily with enzalutamide at CrCl 30-59; the retrieved RX mirror still states 0.5 mg daily for that setting. Breast-cancer monotherapy is a separate regimen.
What to reconcile: Keep the conflict flagged and prioritize the exact official product label; do not average the doses or transfer the monotherapy schedule.
Open this note and its source references| CrCl | Labeled breast-cancer indication | HRR-mutated mCRPC with enzalutamide |
|---|---|---|
| 30-59 mL/min | 0.75 mg once daily | 0.35 mg once daily |
| 15-29 mL/min | 0.5 mg once daily | 0.25 mg once daily |
Do not substitute the breast-cancer dose for the enzalutamide combination dose.
RDM32-talazoparib-talzenna-1 · Source locator: 2.6
This summary does not assign a dialysis regimen or replace the drug-interaction and marrow-toxicity dose modifications.
RDM32-talazoparib-talzenna-2 · Source locator: 2; 8.7
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=talazoparib-talzenna&s1=RDM32-label-talazoparib-talzenna&h1=d55bd7e09456a9b1c7feb1d49e17d7013ebceb1acd2fc3d0fa649bb769beed99